Dosage is increased over 14 days to 7.5mg phentermine/46mg topiramate, with additional titration to the top dose if weight loss is inadequate.54 Four centrally-acting noradrenergic agents (phentermine, diethylpropion, phendimetrazine, benzphetamine) are FDA-approved for the “short-term” (usually considered ≤12 weeks) management of obesity. Pooled, sample size-weighted, estimates and confidence intervals for weight loss at 1 year were calculated from the primary studies. Automated searches were supplemented by examination of expert recommendation reports and bibliographic references from included research studies, and searches of for each identified medication. It was originally used as a short-term medication to jump-start weight loss, but now newer medical guidelines have added it to long-term therapy. Phentermine is the oldest and most widely used weight loss medication. It is also semaglutide, but approved to treat type 2 diabetes. For each individual case, the doctor and patient should discuss the patient’s current health issues, other medications, and family medical history. The top anti-obesity medications (AOMs) at that time were phentermine, marketed as Lomaira and Adipex-P, and orlistat, marketed as Xenical and Alli. However, the authors noted that the "magnitude of these effects is small, and the clinical relevance is uncertain." Supplementation with CLA as a free fatty acid (but not as a triacylglycerol) also increased lean body mass compared with placebo. At the end of the study, body fat mass dropped by significant amounts with both forms of CLA compared with placebo; reductions, on average, were 6.9% with CLA as a free fatty acid and 8.7% with the triacylglycerol form. At the end of the study, participants taking the herbal product lost a mean of 5.1 kg compared to 0.3 kg for those taking the placebo. These findings indicate that the higher doses of caffeine might be responsible for the observed effects. The 50 or 75 mg caffeine plus G-hesperidin also significantly reduced abdominal fat compared to placebo, whereas the G-hesperidin alone or with only 25 mg caffeine did not significantly affect BMI or abdominal fat. The 75 mg caffeine plus G-hesperidin significantly reduced BMI by a mean of 0.56 versus 0.02 for placebo. Gastrointestinal side effects were reported with semaglutide and discontinuation of treatment due to side effects was reported to be higher than with placebo in one trial (3.4% with semaglutide vs 0% with placebo) . Many clinicians are now comfortable prescribing liraglutide in overweight diabetic patients, but they seem to be hesitant to use it for obesity without diabetes. Liraglutide is especially beneficial in overweight or obese diabetic patients as it has also been established as an effective therapy for better glycemic control in type 2 diabetics as an adjunct to oral anti-diabetic medications and/or insulin . Like other FDA-approved pharmacotherapy, naltrexone-bupropion can be prescribed for the appropriate patient population to benefit from its effects on weight loss and metabolic profile. With other weight loss drugs, perhaps a third of patients might expect to lose 10% of their body weight. Perhaps 50% of people who take other types of weight loss medications will lose 5% of their body weight. If you look at the phase 3 clinical trials, the amount of weight loss achieved with semaglutide 2.4 mg is double that observed with currently available obesity medications. Novo Nordisk said that people who used the oral medication during phase 3 of clinical trials lost about 14% of their body weight, while those who stayed on the treatment lost about 17%. Prescription weight loss drugs are a popular and effective treatment for obesity and for health problems related to being overweight. Lark offers 24/7 health coaching from your smartphone. If you’re taking an injectable medication, be sure you know how to administer it properly. That’s because the medication works by blocking fat absorption. Regulation, and reduce energy levels so it’s harder to do things like be physically active and prepare healthy food. This guide walks through the main groups of FDA approved weight loss drugs, how they work, likely benefits, safety considerations, and practical tips about access and cost.Some are prescription pills, some are prescription injectables, and one is an over-the-counter option.Additionally, buying from unauthorized sources may not provide the necessary guidance and support from a healthcare professional to ensure safe and effective use of the drug.For some patients, a pill may be a more acceptable option, which could help us reach people who might not otherwise consider treatment,” added Bennett.Up to 25% lost at least 10% of their body weight.For example, the popular diabetes drugs Victoza, also from Novo Nordisk, and Jardiance have been approved as treatments to reduce the risk of heart attack, stroke and death in heart patients.And ask about the possible benefits and risks of each drug.The odds ratios and 95% credible intervals (CrI) for achieving at least 5% weight loss at one year in phase III clinical trials for liraglutide as compared with placebo and other FDA approved long‐term weight loss agents. Orlistat is the only drug of its kind that's approved in the U.S. Also, take a multivitamin at least 2 hours before or after taking orlistat because the drug temporarily makes it harder for your body to absorb vitamins A, D, E, and K. Rare cases of severe liver injury have been reported in people taking orlistat, but it's not certain that the drug caused those problems. It also can't be mixed with pain relievers or other drugs that contain opioids. AOMs may counter the effects of metabolic adaptation and prevent weight regain. Additionally, drugs targeting hunger or satiety signaling have been actively studied and have shown increased adoption by physicians. Keep in mind that obesity is a disease, and no drug can permanently “cure” it. CDC Lifestyle Coach, Certified Diabetes Care and Education Specialist, and expert in nutrition, public health, and healthy lifestyle choices Treatment with Zepbound, whose generic name is tirzepatide, led to improvements in both sets of patients, according to results published in June in the New England Journal of Medicine. Without insurance coverage, Zepbound costs $1,060 per month, but Lilly offers discounts, coupons and a lower-priced version that comes in a vial that patients use a syringe to inject instead of an auto-injector pen. Novo Nordisk is developing an oral version of semaglutide (50 mg)specifically for obesity. In May 2025, they reported 39 new GLP-1 medications in development. The average weight loss in real-world studies is 9%. If compounded semaglutide is used, we ensure it comes from a reliable pharmacy and monitor your progress closely. As you read through the information below, our goal is to help you feel informed, supported, and prepared to make decisions that reflect your personal health needs. FDA approves treatment for serious liver disease known as ‘MASH’. Test of Life section. was health RSS Phentermine is an appetite suppressant while topiramate aids in binge eating and cravings; the combination of these two medicines enhances weight loss results. On the contrary, non-FDA approved substances have not been tested under strict regulatory guidelines and have not been required to show superior results to placebo or diet and exercise alone. Several medications require additional testing even after FDA approval. The medication comes prefilled in a pen—a device that looks like a fat magic marker or a cigar. Some patients might be concerned about having to inject themselves once a week. Nausea and, in some cases, vomiting can be a real problem for those taking this drug; for some, diarrhea or constipation can be an issue. This hasn’t been observed in humans, but out of precaution, the drug is not prescribed to individuals with a personal or family history of these cancers. However, this drug class has been linked to rare thyroid cancers in rats. It is an oral medication that most commonly causes gastrointestinal adverse effects, including steatorrhea due to impaired fat absorption, which may lead to a deficiency of fat-soluble vitamins and nutrients . Orlistat has been shown to be effective for achieving weight loss of 5% or more from baseline. Orlistat is a pancreatic lipase and gastric lipase inhibitor that can lead to a decrease in fat absorption by as much as 30% contributing to weight loss 12,13. We shouldn't expect that any drug is a magic bullet, or that one medication is necessarily going to work for everyone. Semaglutide, which can be titrated up to 2.4 mg per injection, was studied purely for weight loss. GLP-1 receptor agonist medications provide a steady supply of this hormone. It belongs to a class of drugs that's been around for quite a number of years. Once you treat the disease, the patient should stay on the treatment that works long term.But Mounjaro likely leads to greater weight loss than Wegovy.Eli Lilly, the maker of the drug Mounjaro, said Thursday it expects the medication could be approved by the U.S.In these instances, the choice may come down to your other diabetes treatment goals and the cost of the medications.Of the 551 participants that entered the run‐in, 422 (77%) lost more than 5% of the screening body weight and were randomized to liraglutide 3.0 mg or placebo.Along with diet and exercise, CONTRAVE, a weight-loss pill, is for adults with obesity or adults who are overweight and have weight-related medical problems. Are FDA Approved Weight Loss Medications Right for You? Increasing fiber, fluids, and protein consumption can help reduce constipation and loss of muscle mass from rapid weight loss. A successful eating plan for weight loss can include these strategies. A weight loss program like Lark includes these elements. For example, getting more sleep can improve weight loss. When your body absorbs less dietary fat, you’re getting fewer calories which can help you lose weight. "The drugs prompt the body to produce more insulin after eating, limiting the elevation of blood sugar levels after meals, something particularly crucial for people with type 2 diabetes," says Dr. Caballero. A weight-loss drug described as a 'game-changer' by obesity researchers has just been approved by the US Food and Drug Administration (FDA), representing the first time the agency has endorsed such a treatment in several years. "A brand new effective pill for weight loss gives people greater flexibility to choose a GLP-1 treatment that can fit in their daily routine and preferences." By integrating supplements as a complementary tool rather than a standalone solution, individuals can better reach and maintain their weight loss goals effectively. While weight loss supplements can provide some assistance, they should never be viewed as a sole solution. The effectiveness of over-the-counter weight loss supplements can be quite variable, and many of these products provide only modest results. Assess the ingredient list to ensure it contains components that are backed by scientific evidence for their efficacy in weight loss. It was formerly only used for weight loss, but now it can be marketed to help reduce the risk of cardiovascular disease. In comparison to clinical trials participants taking Plenity did not have more adverse events than participants taking placebo. This medication although FDA approved and requiring a prescription is not covered by medical insurance and retails for approximately $98 a month. Quiz: Test your knowledge about weight-loss pills The weight loss approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding obesity drug market, which Wall Street analysts believe could grow to a $100 billion industry by 2030. Before Wednesday's approval, many patients had used tirzepatide off-label for weight loss, adding to a frenzy of demand for treatments that can help patients shed pounds, such as Novo Nordisk's Wegovy and Ozempic. The active ingredient in the drug, tirzepatide, has already been approved for the treatment of Type 2 diabetes under the name Mounjaro since May 2022. This is also true with some insurance plans like Medicare that do not cover weight loss medications. Must people remain on weight loss medication for life? Many over-the-counter remedies can have major effects on your health in ways you might not predict.The following is evidence from clinical trials on how it effectively promoted weight loss versus those on placebo.The FDA approved tirzepatide for treating type 2 diabetes in May 2022 and is now reviewing whether to approve it to treat obesity.Many clinicians are happy to prescribe compounded GLP-1 weight loss drugs, but some experts caution that the limited oversight may expose patients to unnecessary risks.For about two years, compounded versions of semaglutide and tirzepatide were permitted in the U.S. due to shortages.When you volunteer to take part in a clinical study, you help doctors and researchers learn more about disease and improve health care for people in the future.But in one of the dose optimization studies, an asymptomatic patient experienced potential drug-induced liver injury, which resolved after discontinuation of danuglipron. For example, popular diabetes drugs Jardiance and Novo Nordisk’s Victoza now have approvals for reducing risk of heart attack, stroke and death in heart patients. Like other weight-loss drugs, it’s to be used along with exercise, a healthy diet and other steps like keeping a food diary. “If they are eligible, we discuss medications or surgery.” She explains that our bodies are not programmed for weight loss, especially extreme weight loss. In humans, however, the evidence on whether Garcinia cambogia or HCA is effective for weight loss is conflicting, and any effects it has appear to be small 6,17, . Only one clinical trial has been conducted on the possible weight-loss effects of fucoxanthin. However, 3.2 g/day CLA (isomer mixture, mainly c9,t11-50% and t10,c12-80%) combined with aerobic exercise for 8 weeks did not reduce body fat compared to placebo in 28 young women with obesity . Although CLA appears to reduce body fat mass in animals , results from human studies suggest that its effects are small and of questionable clinical relevance . GLP-1 therapy may provide the support your body needs, but it works best when combined with healthy habits and consistent follow-up care. GLP-1 medications can support blood sugar balance, but individuals with significant glucose fluctuations may need more frequent monitoring. Patients who adopt these habits often feel more confident and comfortable as they move through treatment.Another important part of safety involves reviewing your history of diabetes, thyroid disease, or gastrointestinal conditions. Each of these drugs has a unique mechanism of action, but they all share the goal of helping individuals achieve and maintain a healthy weight. Remember to always consult with a healthcare professional before starting any new medication or weight loss program. A larger group of participants is involved, and the drug is tested against a placebo to determine its effectiveness in achieving weight loss. FDA approves weight loss drug Zepbound to treat obstructive sleep apnea In studies, it's helped people achieve mild weight loss. These drugs are recommended for people who are obese. This is true for many medications that control other health conditions. The U.S. Food and Drug Administration's approval handed drugmaker Novo Nordisk an edge over rival Eli Lilly in the race to market an obesity pill. The following are medicines currently approved by the FDA for weight loss. “Weight loss drugs are among the most sought-after products sold in the U.S.,” said Dr. Taraneh Soleymani, director of Obesity Medicine at Penn State Health Medical Group. This is the first drug that can predicably get us there for the majority of patients. This is a once-weekly injectable, which is more tolerable way of managing obesity vs. other treatments. In fact, we were going in the wrong direction, with one obesity treatment withdrawn. Physical function scores also improved in the semaglutide group vs. placebo. Understanding which supplements have been approved and the science behind them can aid in making informed decisions. But very few people want to be on these for life. He argues for investing in preventive strategies, such as healthier foods and changing the food system. So Type 2 diabetes, fatty liver disease, sleep apnea and the sleep disruptions and the cardiovascular risk that that leads to. Obesity is a disease that puts people's lives at risk. It can also reduce the risk of regaining weight after losing weight. Orlistat works by helping your body absorb less fat from the meals you eat. That’s because when it was approved in 1959, there were no long-term studies to show that it was safe. But, it’s also a controlled substance and comes with health risks. Eli Lilly, Novo Nordisk negotiating deal with Trump admin on obesity drug prices Whether or not these perceived barriers will influence the “real world” adoption of liraglutide for weight management remains to be seen. This includes initiation of comprehensive lifestyle intervention programs and pharmacotherapy in individuals with BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 with comorbid conditions like type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea if lifestyle modification alone is not effective 29. Guidelines from the American Heart Association/American College of Cardiology/The Obesity Society recommend using a multifactorial approach to manage obesity 28. The primary endpoint is usually a non‐inferiority comparison to placebo, often with a pre‐specified caveat that should non‐inferiority be met, a test for superiority would subsequently be conducted. He noted numerous life-threatening diseases — from heart attacks and strokes to diabetes — that are linked to obesity. About 70% of adult Americans have obesity or overweight, the FDA noted. In announcing the approval, the FDA cited the growing public health concern over excess weight. Common side effects from the drug include nausea, diarrhea, constipation and vomiting. Eli Lilly & Co., maker of Zepbound, says it shows greater weight loss at a lower list price than Wegovy. However, due to its sympathomimetic effects, it should not be used in patients with uncontrolled hypertension. Discontinuation of treatment related to adverse effects including nausea, vomiting, constipation, dry mouth, and dizziness has been reported . The side effects that resulted in discontinuation of treatment included blurry vision, headaches, insomnia, paresthesia, irritability, dizziness, anxiety, and depression . Over 40% of participants taking phentermine-topiramate achieved 5% weight loss over 20 weeks . The combination of phentermine with topiramate has been approved by FDA for the management of obesity. Some people may be prescribed up to 4.5 milligrams. The company has a patient assistance program for people who qualify. Liraglutide has been shown in studies to cause thyroid tumors in animals, but it's not yet known if it can cause thyroid cancer in people. If you don't lose 4% of your weight after 16 weeks of taking liraglutide, your doctor may tell you to stop taking it because it's unlikely to work for you. Liraglutide has been shown in studies to cause thyroid tumors in animals, but it is not yet known if it can cause thyroid cancer in people. Although researchers are still chipping away at obesity’s complex combination of causes—including genetics, environment and behaviour—many support the idea that biology plays a significant part. And some researchers are investigating the monoclonal antibody bimagrumab, which increases muscle mass while decreasing fat. And biopharmaceutical company Amgen, based in Thousand Oaks, California, is pursuing a drug that activates the GLP-1 receptor while thwarting the GIP receptor. Liraglutide 1.8 mg was recently shown to have cardiovascular benefit in a large outcomes trial; applicability of these results for the 3.0 mg formulation in a more diverse weight loss population at high cardiovascular risk is not currently known. Comparative data suggest that weight loss with liraglutide is greater than that seen with orlistat or lorcaserin, but slightly less that seen with phentermine/topiramate. The most common adverse effects were gastrointestinal and primarily occurred early in the treatment course. Not all GLP-1s are approved for obesity treatment, and this analysis includes all FDA-approved GLP-1s, including those approved for obesity (Saxenda, Weogvy, Zepbound) as well as those approved for type 2 diabetes (see Table 1). Any savings on health spending because of obesity drugs may take many years and may not accrue to the Medicaid program if individuals experience shifts in coverage, so states may not be factoring long-term savings into coverage decisions. However, almost four in ten adults and a quarter of children with Medicaid have obesity, meaning expanding Medicaid coverage of these drugs could provide access to effective obesity treatments for millions. Are there FDA-approved tirzepatide tablets? Because these are prescription injectables, they are used under medical supervision and are classified among the most effective FDA approved weight loss drugs available today. Both kinds are considered FDA approved weight loss drugs when they have formal FDA approval for chronic weight management. This guide walks through the main groups of FDA approved weight loss drugs, how they work, likely benefits, safety considerations, and practical tips about access and cost. The term FDA approved weight loss drugs refers to medicines that the U.S. Clinical trials have shown that semaglutide can lead to significant weight loss, often exceeding 15% of body weight when combined with lifestyle modifications. Although more research into all of the aforementioned medications is needed, current data provide sufficient evidence to support their use. Semaglutide appears to be the most effective of the five drugs, but tolerability and feasibility of subcutaneous administration remain an issue. Medical management should be considered when lifestyle modifications alone are insufficient to maintain weight loss. Discontinuation of treatment has been reported as well due to gastrointestinal side effects, thus making it a favorable option for only those who can tolerate it. An extra yearly reduction of 4.8% in total body weight (average 4.4 kg) has been seen, accompanied by side symptoms such as nausea, headache, and dizziness.The promise of fast and easy weight loss is hard to resist.In this trial, those randomized to receive the highest approved dosage of Zepbound (15 mg once weekly) lost on average 18% of their body weight compared to those randomized to placebo.The change in body weight from baseline to 24 weeks for patients who switched from semaglutide to orforglipron was –0.1 kg vs 9.4 kg for placebo.6We provide access to the most effective FDA-approved weight loss medications as part of a comprehensive treatment plan.Readers should verify details directly with platforms and healthcare providers.When your body absorbs less dietary fat, you’re getting fewer calories which can help you lose weight.In the 2000s, the US Food and Drug Administration (FDA) began approving drugs that mimicked GLP-1 as type 2 diabetes treatments (see ‘Weight busters’). Until last week, Wegovy was only FDA-approved as a weight loss medication. Wegovy is an injectable weight loss medication that contains 2.4 milligrams of semaglutide. Weight loss medications are tools for weight loss that serve several purposes. Orlistat is the only weight loss medication approved for use in children. Wegovy is FDA approved for weight loss and Ozempic is approved for use in Type II diabetes. But, you're only eligible for the surgery, if you have a BMI over 40, or a BMI over 35 and another obesity-related condition like heart-disease, hypertension, or type 2 diabetes. On average, individuals can expect to lose between 5 and 10 percent of their starting weight within the first year of treatment. In rare cases, more serious side effects can occur, such as increased heart rate and blood pressure, so it’s essential to carefully monitor side effects and report any concerns to a healthcare professional. Compared to the placebo group, those receiving Xanthigen lost significantly more body weight by the end of the trial (mean loss of 6.9 kg vs. 1.4 kg for placebo in participants with NAFLD; mean loss of 6.3 kg vs. 1.4 kg for placebo in those without NAFLD). The authors of a systematic review and meta-analysis of seven randomized controlled trials concluded that taking 2.4–6 g/day CLA for 6–12 months reduces body weight by a mean of 0.7 kg and body fat by a mean of 1.33 kg compared to placebo . In contrast, those in the placebo group did not lose a significant amount of body weight (0.09 kg) or body fat (0.1 kg) compared to baseline. In this study, Coleus forskohlii extract did not affect body weight, but it did significantly decrease mean body fat by about 4% compared with about 1% for placebo. Compared to placebo, Coleus forskohlii extract had no effect on body weight, appetite, caloric intake, or macronutrient intake. While no specific vitamin or supplement is considered a “treatment” for obesity or overweight, certain ones help support metabolic health. With prescription medications, a healthcare professional can weigh all factors affecting the patient’s lifestyle and BMI and monitor progress and side effects. Medicare does not cover weight loss drugs. While GLP-1s have grabbed a lot of headlines, they are only the latest in a long history of evolving weight loss medications. From prescription medications to medical devices and bariatric surgery, there is a range of solutions available for those who qualify. One exciting development in weight loss solutions is the trend towards personalized medicine. Incorporating physical activity into your routine is essential in conjunction with any weight loss solution. Adopting a healthy, balanced diet is crucial for maintaining a healthy weight. It is important to remember that these medications are only approved for people who meet certain criteria. Also, initial research suggests that retatrutide, a triple hormone receptor agonist (acting on receptors for GLP-1, GIP, and CGCR), may lead to weight loss of up to 25% in people with diabetes. These discomforts were enough for some in the group to discontinue treatment, but for many who didn't feel the side effects – or grimaced through them – potentially life-transforming weight loss was achievable. On Friday, the agency announced that Wegovy (semaglutide) had been approved for chronic weight management in adults who are either obese or overweight, and who have at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol). "No other drug has come close to producing this level of weight loss – this really is a game-changer," obesity researcher Rachel Batterham from University College London said at the time. Anaerobic exercise, such as weight training, is also good because it adds muscle mass to your body. To keep the weight off, you must eat a healthy diet and be physically active on a regular basis. They may only provide temporary weight loss. Or they are used with people who have a high body mass index (BMI). Weight loss medications aren’t a “set it and forget it” situation."In light of increasing rates of both obesity and overweight in the United States, today's approval addresses an unmet medical need."These medications have side effects, some of which could be severe.The agency also said that Zepbound should not be used in combination with Mounjaro or another weight loss or diabetes drug targeting GLP-1 because "the safety and effectiveness of coadministration" has not been established.The possible superiority of semaglutide with a similar risk of adverse events makes it an excellent choice of drug for the management of obesity in the patient population willing to take subcutaneous medication .FDA-approved weight loss medications help people reach and maintain a healthy weight.The authors of a systematic review and meta-analysis of six randomized controlled trials in a total of 203 participants concluded that 5–30 g pyruvate for 3–6 weeks reduces body weight by a mean of 0.72 kg and body fat by a mean of 0.54 kg compared to placebo .Be sure to inform your health care provider about all the medicines you take, including over-the-counter products, vitamins, herbal remedies, and health supplements – especially if you use insulin or other diabetes medicines.This medication is also helpful if you have substance use disorder or if your main issue is sugar cravings. Sign up to get the latest news about CONTRAVE, weight-loss tips, special offers, and more. In just a few minutes, you'll receive personalized results that you can share with your healthcare provider. Looking for a healthcare provider to discuss CONTRAVE with? The pharma giant already has one GLP-1 available in pill form under the name Rybelsus. In May, Novo Nordisk announced seeking regulatory approval of an oral version of Wegovy for weight management. However, the real competition will not be from branded Saxenda, but Wegovy (semaglutide, Novo Nordisk) and Zepbound (tirzepatide, Eli Lilly). A generic Saxenda expands our treatment options. The medication should be in combination with a reduced calorie diet and increased physical activity, according to the press release. Wegovy marks an important time in medicine as it is the first FDA-approved adult weight loss drug since 2014. Those on Wegovy lost an average of 6.2 percent of their starting body weight versus those in placebo. Those who received Wegovy lost an average of 12.4 percent of their starting body weight versus those on placebo. In addition to improving blood sugar, this drug also seems to help people lose weight. There's a healthier way to lose weight with weight-loss medication. Lifestyle changes that promote weight loss might also improve mood and energy levels and lower the risk of heart disease, diabetes, and some cancers . Individuals taking dietary supplements and medications on a regular basis should discuss their use with their health care provider. Hardly a day goes by without another headline touting the benefits of new Food and Drug Administration (FDA)-approved injectable weight loss medications. If you define second generation obesity medications as those that can achieve weight loss of 15% or more when coupled with a lifestyle intervention, then this is the first member of that second generation of obesity medications. Semaglutide 2.4 mg should not be used in combination with other semaglutide-containing products, other GLP-1 receptor agonists or other products intended for weight loss, including prescription drugs, over-the-counter drugs and herbal products, according to the release. Weekly semaglutide 2.4 mg (Wegovy, Novo Nordisk), a GLP-1 receptor agonist, is the first-approved drug for chronic weight management in adults with general obesity or overweight since 2014. The authors commented that the cause of this finding might have been stored vitamin D in body fat and skeletal muscle that was released during weight loss.Let your healthcare provider help you understand how these medications can support your weight loss journey.But this view is changing as research shows the health impacts of obesity.Following the recommended dosage schedule for Mounjaro or Zepbound helps limit these side effects.Some, such as fluoxetine, were found to promote weight loss for up to six months, but not longer-term.60Bupropion, a norepinephrine and dopamine reuptake inhibitor, was tested as monotherapy for up to one year as a weight loss medication.Nevertheless, liraglutide is contraindicated in patients with a personal or family history of MTC or MEN 9.Doctors prescribe these drugs for more than 12 weeks, helping people lose more weight than they would on their own.. Mounjaro and Zepbound are two brand names for the medication tirzepatide. You’d essentially be doubling up on your medication if you used both. Contact the customer support department for your health insurance plan to discuss details about coverage. Like the injectable version of Wegovy, the pill is intended to help patients shed body weight when coupled with diet and exercise. A pill form of weight-loss drug Wegovy, manufactured by Danish drugmaker Novo Nordisk, is now available in the U.S., giving Americans access to an oral medication to treat obesity. You could lose 10% of your body weight or more with these drugs, but you may have to take them for life to keep the weight off. FDA-approved weight loss drugs like Wegovy, Zepbound, and Qsymia offer powerful tools for managing obesity and improving health. When combined with a healthy diet and exercise, FDA-approved weight-loss drugs can help you lose 3% to 12% of your body weight in a year. FDA-approved weight loss medications help people reach and maintain a healthy weight. Giving leptin supplements to mice that lacked it reduced their hunger and body weight. The WHO recommends healthier diets and physical activity to reduce obesity, but medication might help when lifestyle changes aren’t enough. With extra weight often comes heightened risk of health conditions such as type 2 diabetes, heart disease and certain cancers. These drugs are arriving in an era in which obesity is growing exponentially. The primary endpoint was change in body weight among the intention‐to‐treat (ITT) population at the end of 20 weeks 3. As a result, liraglutide was also developed as a weight loss agent and its 3.0 mg daily dose has shown encouraging results in multiple phase III clinical trials (see below) 3, 4, 5, 6, 7, 8. Results from clinical trials repeatedly demonstrated the ability of GLP‐1 analogs to induce weight loss 2. Mounjaro, approved last year, is already Lilly’s second-largest seller behind only the diabetes drug Trulicity. Quitting it can lead to regaining much of the weight you lost. You may have to stay on Zepbound for life for weight management. Tirzepatide has been shown in studies to cause thyroid tumors in animals, but it's not yet known if it can cause thyroid cancer in people. GLP-1 weight loss medication injections do not hurt. We handle the Prior Authorization process for Wegovy and Zepbound to help you access FDA-approved medications at the lowest possible cost. While many med spas and online clinics in Colorado now offer access to GLP-1 medications like Wegovy® (semaglutide) and Zepbound® (tirzepatide), who prescribes your medication matters just as much as the medication itself. Your body is hardwired to fight back against weight loss, making it difficult to keep the pounds off. The authors concluded that daily doses of 137 to 1,000 mcg chromium for 8 to 26 weeks reduce body weight by 0.5 kg and percent body fat by 0.46%. Also in 2013, a systematic review and meta-analysis of 11 randomized controlled trials (including most of the trials evaluated in the Cochrane Review) examined the effects of chromium supplementation in a total of 866 individuals with overweight or obesity . Several studies have evaluated the effects of chromium supplements, usually in the form of chromium picolinate, on weight loss. They concluded that chitosan appears to be more effective than placebo for short-term weight loss, but most studies have been of poor quality. A 2016 systematic review and meta-analysis combined the results from nine carnitine supplementation clinical trials in adults (including the two described above) that assessed weight loss .The trials included a total of 911 participants. Desipramine, nortriptyline, and protriptyline have variable effects on weight. Weight-positive medications in the tricyclic antidepressant category include amitriptyline, doxepin, and imipramine. Many antidepressants are weight-positive (cause weight gain), some are weight-neutral, and at least one is weight-negative (causes weight loss). This relationship can allow for dosage adjustments or alternative medications if one seems like a better fit for the patient. A subset of clinical-trial participants who ceased taking semaglutide and stopped the study’s lifestyle interventions regained about two-thirds of their lost weight after one year. Eli Lilly is conducting early-stage clinical trials with drugs that target GIP alone, which Holst says will resolve the ongoing debate. It can also mimic GIP, “but it doesn’t really matter in patients with diabetes and obesity, because the GIP part doesn’t really do anything,” says Holst. Despite the uncertainties, the levels of weight loss following tirzepatide treatment approach those typically achievable only through bariatric surgery. Historically, it hasn’t been possible to safely decrease body weight by more than 10% through pharmacological methods, says Timo Müller, a biologist and director of the Helmholtz Munich Institute for Diabetes and Obesity. Eli Lilly made a similar deal for its weight loss pill. In clinical trials, that treatment reduced weight by about 15% after 68 weeks, results showed. We are confident that the expansion of Wegovy to a pill will help patients who may have not sought or accepted treatment before.– Dave Moore, Novo Nordisk EVP of U.S. operations Since Mounjaro and Zepbound both contain tirzepatide, they have similar side effects. Over a period of several weeks, your prescriber will slowly raise your dose until you have an ideal response without too many side effects. It’s also approved to treat moderate-to-severe OSA for adults who are considered obese. It should be combined with a diabetes-friendly diet and regular exercise. Tirzepatide works by mimicking GIP and GLP-1 (two gut hormones in the body). This allows meaningful amounts of the medication to enter the bloodstream before digestive processes destroy it. The injectable form bypasses these issues entirely, delivering the medication directly into subcutaneous tissue where it's gradually absorbed into the bloodstream. This groundbreaking approval represents more than just convenience—it signals a fundamental shift in how we approach long-term weight management. Our work focuses on addressing interconnected issues such as weight gain, fatigue, brain fog, and hormonal imbalances by uncovering and correcting their root causes. Compounded semaglutide uses the same active ingredient as FDA-approved products but is prepared by compounding pharmacies rather than the original manufacturer. The FDA does not verify safety, effectiveness, or quality of compounded drugs before marketing. MEDVi, LLC operates a telehealth platform that coordinates access to compounded semaglutide. This means they both work the same way in the body. Many times, this happens when a medication has multiple uses. It’s not unusual for a medication to have more than one brand name. Although both are GLP-1 drugs, liraglutide is about half as effective as the 2.4-mg dose of semaglutide (Wegovy), Garvey says. The weight loss benefit comes thanks to the drug's ability to suppress appetite by acting centrally in the brain. Thanks to the new FDA approval, an even higher dose of semaglutide, 2.4 mg, will now be sold specifically for weight loss under the brand name Wegovy. For summaries of new drug candidates and trial results, see this roundup on new weight loss drugs. For an overview of current and emerging prescription options, see this review of top weight loss medications. Our clinic specializes in offering cutting-edge treatments, including semaglutide therapy, to help you achieve your weight loss goals effectively and sustainably. These medications offer a valuable tool for individuals seeking to manage their weight and improve their health. The landscape of weight management has evolved significantly in recent years, with the FDA approving several new medications to aid in weight loss. Semaglutide has been emerging as a promising pharmacotherapy for weight management when combined with lifestyle modifications. Once-daily dosing in comparison to weekly dosing of semaglutide also creates comparatively more inconvenience. More studies need to be performed to further assess the long-term safety and benefits related to cardiovascular and metabolic health. The combination of naltrexone, an opioid receptor antagonist, and bupropion, a norepinephrine-dopamine reuptake inhibitor, is used for the management of obesity . In 2022, Wegovy received its second FDA approval, this time to cater to pediatric patients aged 12 years and above. You should tell your healthcare provider if you taking Wegovy with insulin or a substance that triggers insulin secretion. Should you have or have had a history of the following, please inform your healthcare provider immediately. During the beginning of the trial, patients’ average age was 46 years old, with 74 percent being women. Moreover, people taking Wegovy must also be on a lower calorie diet and increase their physical activity. There are ways to save on semaglutide, which is available as brand-name Wegovy. Like semaglutide, tirzepatide mimics GLP-1. It’s also sold as Mounjaro to treat adults living with Type 2 diabetes. Every medication we dispense is sourced through legitimate pharmaceutical supply chains, properly stored, and prescribed only after thorough clinical review. NICE guidelines emphasise that successful treatment often involves long-term medication alongside lifestyle modifications. Expanding treatment options increases the likelihood that more people will find an approach they can sustain long-term. Needle phobia affects approximately 10% of the population, with many people avoiding necessary medical treatments due to injection anxiety. Additional side effects are listed for each medicine. They share common side effects, including constipation, dizziness, dry mouth, diarrhea, and nausea. Orlistat is the only medicine of its kind to be approved in the U.S. Also included is information on how they work, common side effects, and warnings for each. Because these medications were approved prior to the requirements for long-term trials with adequate power to ascertain clinical endpoints, an adverse effect of noradrenergic obesity drugs on cardiovascular disease events cannot be excluded, and is of concern given their known effect on heart rate and blood pressure. A PubMed search was conducted from inception to September 15, 2013 to find long-term (≥1 y) placebo-controlled randomized clinical trials and meta-analyses investigating drugs currently FDA-approved alone or in combination for an obesity or weight management indication. Medications approved for long-term obesity treatment, when used as an adjunct to lifestyle intervention, lead to greater mean weight loss and an increased likelihood of achieving clinically-meaningful 1-year weight loss relative to placebo. The most common FDA approved weight loss medications work by either suppressing appetite, increasing feelings of fullness, or reducing the absorption of dietary fats. FDA approved weight loss solutions are medications that have been reviewed and authorized by the U.S. Remember, while FDA-approved weight loss treatments can aid in your journey, incorporating healthy lifestyle changes and maintaining a well-balanced diet will ultimately lead to sustained success. Research in weight loss treatments continues to evolve, with new medications and surgical techniques on the horizon. It is a once-a-week shot that helps adults who are overweight or have obesity lose weight by controlling hunger and improving blood sugar. Some pills stop the body from taking in fat from food, which reduces the calories you get. As a result, they consume fewer calories, which aids in weight loss. Is the newly approved semaglutide any different? Individuals should not rely solely on medication for weight control; lifestyle changes are critical. Regular follow-up appointments with a healthcare provider are essential to assess the ongoing need for the medication and monitor health responses. Some medications are intended for short-term use, usually around a few weeks to a few months, while others are meant for long-term management over a year or more. Healthcare providers typically recommend this comprehensive approach because it enhances overall effectiveness and supports a more sustainable weight loss journey. Compounded versions of medications are made by compounding pharmacies, often to tailor a medication to specific patient needs, like an allergy to an inactive ingredient. These medications are not made or packaged by the original manufacturers. However, the FDA warns against buying medications from any source other than a state-licensed pharmacy. Older AOMs also have indications based on BMI and may be contraindicated for use with certain other medications. Bupropion (Wellbutrin), an aminoketone, is considered weight-negative and is prescribed both to assist in weight loss and to treat depression. Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that was FDA approved in 2021 for chronic weight management. Most prescription weight-loss drugs work by making you feel less hungry or fuller. For example, you shouldn't take prescription weight-loss drugs if you're trying to get pregnant, are pregnant or are breastfeeding. Then your provider talks with you about the pros and cons of prescription weight-loss drugs. Combination therapies targeting multiple metabolic pathways are also under development, potentially revolutionizing weight management. Developed by Eli Lilly, this once-weekly injection targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, potentially offering greater efficacy than semaglutide. The once-daily injection has demonstrated weight-loss benefits but has been largely overtaken by newer, more effective weekly injections. For individuals of South Asian descent, obesity-related complications develop at a lower BMI. Moreover, the economic and societal burden of obesity is growing, spurring demand for comprehensive solutions. KFF links each drug’s NDC in the dataset to a drug class using the World Health Organization’s (WHO) Anatomical Therapeutic Chemical (ATC) classification system. Specifically, increased utilization of Ozempic and Wegovy (semaglutide) as well as Mounjaro and Zepbound (tirzepatide) have contributed substantially to recent growth. However, GLP-1s accounted for over 8% of all Medicaid prescription drug spending before rebates in 2024 (up from 1% in 2019). North Carolina eliminated GLP-1 coverage beginning October 2025 due to a budget stalemate in the legislature, but coverage was reinstated in December 2025, bringing the total number of states covering GLP-1s for obesity to 13 as of January 2026. The upfront costs of GLP-1s are an ongoing concern for both public and private payers, and some employers and state Medicaid programs are now restricting coverage, despite recognizing their effectiveness at treating obesity. Those randomized to receive the highest approved dosage of Zepbound (15 mg once weekly) lost on average 12% of their body weight compared to those randomized to placebo. In this trial, those randomized to receive the highest approved dosage of Zepbound (15 mg once weekly) lost on average 18% of their body weight compared to those randomized to placebo. Andrew Kraftson, MD, the director of the weight navigation program at Michigan Medicine in Ann Arbor, believes strongly in the value of medications like semaglutide and understands why people are scrambling to get them. Juliana Simonetti, MD, a co-director of the comprehensive weight management program at the University of Utah in Salt Lake City, says anyone buying compounded drugs from a questionable source runs the risk of using medications that pose safety risks. Many clinicians are happy to prescribe compounded GLP-1 weight loss drugs, but some experts caution that the limited oversight may expose patients to unnecessary risks. But when his weight loss plateaued and he continued to need insulin, his appetite increased. Obesity drugs appear to keep getting better. That’s lower than the cash price for low-dose injectables, but the drugmakers haven’t indicated what they will ultimately charge for higher doses of the pills or what they’ll charge payers. Lilly, meanwhile, has developed its own GLP-1 pill called orforglipron, which is currently under FDA review and is expected to be approved in the next few months. Other OTC weight loss medications are supplements. These drugs can be the answer to years of health challenges for many people. Weight loss medications help with weight loss. Further studies need to be conducted, preferably clinical trials, to yield statistically significant results regarding efficacy as well as adverse events and safety of anti-obesity medications. The possible superiority of semaglutide with a similar risk of adverse events makes it an excellent choice of drug for the management of obesity in the patient population willing to take subcutaneous medication . Food and Drug Administration (FDA) for the treatment of obesity work primarily by reducing appetite and increasing feelings of fullness. The Weight Management webpage from the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health provides several helpful publications on weight control, obesity, physical activity, and related nutritional issues. The best way to lose weight and keep it off is to follow a sensible approach that incorporates a healthy eating plan, reduced caloric intake, and moderate physical activity under the guidance of a heath care provider. Several small human studies have examined whether bitter orange is effective for weight loss .Müller says that tirzepatide might be a more potent activator of the GLP-1 receptor, and that GIP might help to make GLP-1’s side effects more tolerable, allowing for higher doses.Injectables among FDA approved weight loss drugs often produce larger average weight loss in trials, but injections are not the right fit for everyone.In the meantime, UK patients seeking weight loss support have excellent options already available.The public’s view of obesity could shift if it were viewed as a medical condition rather than a social parameter.It’s also a long-term commitment since rebound weight gain is possible if you stop using it. What could 15% weight loss mean for you? However, the calorie reductions did not significantly affect body weight at either 6 weeks or 12 weeks.Your healthcare professional can provide guidance and support throughout your weight loss journey.“Weight loss drugs are among the most sought-after products sold in the U.S.,” said Dr. Taraneh Soleymani, director of Obesity Medicine at Penn State Health Medical Group.Tirzepatide works by mimicking GIP and GLP-1 (two gut hormones in the body).Since Mounjaro and Zepbound both contain tirzepatide, they have similar side effects.But only semaglutide is also approved to lower the risk of serious cardiovascular problems in certain people, with or without diabetes.After that, fen-phen, a diet pill that combined the anorectics phentermine and fenfluramine, had a meteoric rise to fame in the mid-1990s.Mounjaro, also known as tirzepatide, is a novel medication that has been developed by Eli Lilly and Company, a leading pharmaceutical giant. More serious side effects are rare but can include cardiovascular issues, pancreatitis, or mood changes. Common side effects might include gastrointestinal issues such as nausea, diarrhea, or constipation, while others may experience headaches or dizziness. It’s important to note that medication effectiveness is heightened when used in conjunction with lifestyle changes. Individuals should consult a healthcare professional to assess risks and benefits, especially those with a history of substance abuse, heart problems, or certain psychiatric conditions. It’s important to consult a healthcare provider to determine if these options are appropriate based on individual health needs and risk factors. 25 Gut Health Hacks is yours absolutely FREE when you sign up to receive health information from Harvard Medical School. Get the latest in health news delivered to your inbox! You might develop various gastrointestinal side effects, including gas, bloating, indigestion, nausea, or irregular bowel movements. "But whether they can be safely used for all people who simply want to lose an extra 10 to 20 pounds is questionable." To lose weight, especially harmful belly fat, combine diet and exercise Currently, no clear guidelines for the pharmacotherapy of obesity exist and such studies could help develop them. Insufficient data regarding long-term effectiveness and risks of side effects was available. The downside is the subcutaneous route of administration which might be inconvenient for some patients, although weekly dosing makes it a bit more convenient than daily subcutaneous dosing of liraglutide. Ozempic and other weight-loss drugs work by mimicking the GLP-1 hormone, which the body naturally produces after eating. A breakthrough in long-term weight management has sparked demand for a new generation of weight loss drugs. Eating healthily and exercising will always be part of treatment, but many think that these drugs are a promising add-on. According to prescribing information, semaglutide should be used with caution or avoided in patients with history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy. Several telehealth platforms coordinate access to compounded semaglutide. Compounded semaglutide formulations have not undergone independent clinical trials as finished products. Some medicines are approved only for a short period of time, usually no more than 12 weeks. It blocks the amount of fat your body can absorb. One FDA-approved medicine works in your digestive tract. Daily oral GLP-1 pill could be just as effective as weekly shots: Drugmaker Most studies have shown that initial weight loss response at 12 weeks predicts later weight loss at ≥1 year.53, 83, 84 Therefore, if a patient does not lose at least 5% of initial weight after 12 weeks of therapy (after assessment for adherence and, where appropriate, an increase in dosage), that patient is more likely than those achieving this threshold to be exposed to the risks and costs of drug treatment when there is little prospect of long-term benefit. Therefore, medications for obesity treatment must be viewed through the lens of long-term use when evaluating their safety and efficacy. Weight loss achieved through lifestyle modification and bariatric surgery has been shown to result in many such improvements; however, one cannot extrapolate from these studies to assume similar benefits will be attributable to weight loss attained with medications. The scientific literature on drug treatment for obesity is limited, particularly for studies conducted before the requirement for registration of all clinical trials, by short intervention periods, high attrition, inadequate description of methods, and data analyses that used biased approaches to deal with missing data79 or concentrated on results of those completing the trial. Those on drug were more likely to both maintain their initial weight loss (81 vs. 49%) and to lose ≥5% (51 vs. 22%) or ≥10% (26 vs. 6%) additional weight than those taking placebo during follow-up, suggesting a potential role for liraglutide in augmenting weight loss or ameliorating regain after initial weight loss achieved through lifestyle intervention. The FDA has issued detailed warnings about unapproved GLP-1 drugs marketed for weight loss, including products claiming to contain tirzepatide (official FDA safety alert). The FDA approved Ozempic in 2017 as a treatment for Type 2 diabetes alongside diet and exercise if other medications cannot control blood sugar levels well enough. A popular drug currently approved to treat Type 2 diabetes could soon also be approved for weight loss. Among clinically available weight loss medications, liraglutide is the only injectable agent, which may limit is “real‐word” applicability.